Amarin (NASDAQ:AMRN – Get Free Report) will likely be releasing its Q3 2026 results before the market opens on Wednesday, October 28th. Analysts expect the company to post earnings of ($0.0972) per share and revenue of $43.76 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, October 28, 2026 at 8:00 AM ET.
Amarin Stock Performance
Shares of NASDAQ:AMRN opened at $11.79 on Monday. Amarin has a twelve month low of $11.25 and a twelve month high of $20.90. The company’s 50 day moving average is $13.14 and its 200 day moving average is $14.15. The company has a market cap of $249.00 million, a PE ratio of -11.91 and a beta of 0.76.
Wall Street Analysts Forecast Growth
Several analysts have commented on AMRN shares. JPMorgan Chase & Co. started coverage on shares of Amarin in a research note on Friday, August 21st. They set an “underweight” rating and a $13.00 price objective for the company. Wall Street Zen lowered shares of Amarin from a “buy” rating to a “hold” rating in a research note on Saturday, July 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amarin in a research note on Thursday, October 15th. Finally, Zacks Research raised shares of Amarin from a “hold” rating to a “strong-buy” rating in a report on Monday, October 5th. One analyst has rated the stock with a Strong Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Amarin presently has an average rating of “Hold” and a consensus target price of $13.00.
Check Out Our Latest Stock Report on AMRN
About Amarin
Amarin Corporation plc is a biopharmaceutical company focused on developing and commercializing therapies intended to reduce cardiovascular risk. Its principal product is VASCEPA (icosapent ethyl), a prescription omega-3 fatty-acid medicine derived from highly purified eicosapentaenoic acid.
VASCEPA was initially approved in the United States to help lower triglyceride levels in certain patients and later received expanded approval to reduce the risk of cardiovascular events in eligible adults with elevated cardiovascular risk.
Featured Stories
- Five stocks we like better than Amarin
- Newmont’s Record Quarter Shows Why Gold’s Floor Is the Real Story
- Albemarle Upgrade: Can Energy Storage Recharge Lithium’s Leader?
- Consumer Staples Are Up 12% This Year—These 3 Beverage Stocks Are Leading the Way
- Can Planet Fitness Get Its Growth Back in Shape?
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.
